ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant

T. J. ONeill IV, G. Jao, A. Kelkar, B. Pisani

Wake Forest Baptist Health System, Winston Salem, NC

Meeting: 2020 American Transplant Congress

Abstract number: C-270

Keywords: Heart transplant patients, Induction therapy, Rejection, Simulect

Session Information

Session Name: Poster Session C: Heart and VADs: All Topics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: The use of induction therapy after cardiac transplantation remains highly variable, not only in terms of which agent is used, but whether it is used at all. Further, while the dose of basilixmab is standardized, many dosing regimens can be used for anti-thymocyte globulin (ATG). Although the Internal Thoracic Organ Transplant Registry collects data regarding use of induction, including ATG, it does not capture the total dosage received by patients. We sought to characterize the experience at our center using reduced dose of ATG and the subsequent development of allograft rejection and severe infection.

*Methods: We conducted a retrospective analysis of all orthotopic cardiac transplants performed at our center from January 2014 through April 2019 (excluding dual organ). Patients receiving ATG were given 1-3 mg/kg in total. All patients followed the same protocol for tacrolimus, mycophenolate and prednisone. The primary outcome was the composite endpoint of ISHLT ≥2R rejection and infections requiring either anti-infective medication or hospitalization (including bacterial, fungal or viral) within the first 12 months following transplant. Additionally, we assessed infection which developed after a treated rejection.

*Results: 57 patients met the inclusion criteria, of those 29 received ATG (between 1 and 5 total doses, mean =2.5 doses, 1.9 mg/kg total ATG), 11 received basiliximab and 17 received no induction (28 total). Outcome data are displayed in Table 1. In the ATG group, 6 developed a ISHLT ≥2R rejection, 7 developed a severe infection (46% of the total with either complication). In the non-ATG group, 10 patients had a confirmed rejection and 9 developed severe infection (68% of the total). The most common infection was symptomatic CMV requiring antiviral treatment (50% of the total infections). Of those treated for rejection, 3/6 (50%) in the ATG group, 4/10 (40%) in the non-ATG group developed a severe infection in the 12 months following treatment of rejection. There was no significant difference between the groups with respect to rejection or infection alone, but the combined outcome was significantly less likely to occur in the ATG group (p = 0.04). 1 year survival was identical in both groups (100%).

Table 1
Outcome ATG Group (n=29) Non-ATG Group (n=28) p-value
ISHLT ≥2R rejection (%) 6 (21) 10 (36) 0.1
Severe Infection (%) 7 (24) 9 (32) 0.26
Combined Outcome (%) 13 (45) 19 (68) 0.04

*Conclusions: Allograft rejection and infection create significant morbidity in the first year after cardiac transplant. Although ATG is a more potent immunosuppressive agent than basiliximab, this data suggests that a reduced dosage of ATG may be able to decrease risk of significant rejection without increasing the rate of severe infections. Further studies are needed to confirm this finding.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

IV TJONeill, Jao G, Kelkar A, Pisani B. Single Center Experience Using Low-Dose Antithymocycte Globulin for Induction Following Heart Transplant [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/single-center-experience-using-low-dose-antithymocycte-globulin-for-induction-following-heart-transplant/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences